ClinicalTrials.gg
RecruitingNCT04913870ARBASUpdated Dec 20, 2024

Angiotensin Receptor Blockers in Aortic Stenosis

A Phase 4 interventional study of Angiotensin Receptor Blockers and Placebo in Aortic Stenosis and Aortic Valve Stenosis, sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval. Recruiting at 2 sites in 2 countries. Open to participants aged 20 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-12-20.

Sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Feb 2020, registered May 2021).
  • Started Feb 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
20 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Aortic Valve Stenosis with a site in Canada — 23 open to participants now, 36 under way, 1 of them phase 3. Aortic Valve Stenosis · Canada.

Planned enrollment
43rd of 60
144 · median 300
Started
2020
with 2 others
Phase 4
2 of 87
2 open now
Primary completion
2027-02
later than 19 of 35 live
Registered
66th of 87
by date
Lead sponsor
5 of 87
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Among the 87 studies in Aortic Valve Stenosis with a site in Canada, this one is the 43rd largest by planned enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2020, is one of 2 in phase 4, reaches primary completion later than 19 of the 35 other live ones, and was the 66th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

23 of the 87 studies in Aortic Valve Stenosis with a site in Canada are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 20 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Aortic Valve Stenosis with a site in Canada, or all of them as a file.
02

Study summary

This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.

Read the detailed description

Studies support the concept that activation of the renin-angiotensin system may be involved in the progression of valve stenosis and myocardial fibrosis in aortic stenosis. Furthermore recent studies have shown that renin-angiotensin system medication may slow down aortic stenosis progression rate and left ventricle remodeling.

Thus the present study is a randomized control trial to test the efficacy of the angiotensin receptor blocker (ARB) to slow down aortic stenosis progression and left ventricular remodeling/dysfunction in patients with mild-to-moderate aortic stenosis.

03

Conditions studied

  • Aortic Stenosis
  • Aortic Valve Stenosis

Keywords

  • Angiotensin II Receptor Blockers
  • Left ventricular remodeling
  • Valvular heart disease
  • Aortic stenosis
04

Who can participate

Ages eligible
20 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mild to moderate aortic stenosis (peak aortic jet velocity ≥2.5 and \<4m/s)
  • Normal (i.e. ≥50%)
  • Systolic blood pressure >110 mmHg
  • Diastolic blood pressure >70 mmHg

Exclusion criteria

Exclusion Criteria:

  • More than mild aortic or mitral regurgitation, or mitral stenosis
  • Current use or documented indication for renin-angiotensin system medication or Aliskiren
  • Known allergy or intolerance to angiotensin II receptor blockers (ARBs)
  • Alzheimer, dementia or known non-compliant patient
  • Renal dysfunction ( \<30ml/min/1.73m2)
  • Chronic hyperkalemia
  • Diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment
  • Newly diagnosed (\<2 months) or poorly controlled diabetes
  • Pre-existing obstructive coronary artery disease with CCS III-IV angina or recent myocardial infarction (\<3 months)
  • Pregnant or lactating women
  • Patients unable to read, understand or sign research consent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Angiotensin Receptor Blockers

    Angiotensin Receptor Blockers will be given orally once a day for 2 years.

    Drug: Angiotensin Receptor Blockers

  • Placebo comparator
    Placebo

    Participants will receive a matched placebo orally once a day for 2 years.

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in the anatomic progression of aortic stenosis

    Aortic valve calcification (measured by MDCT)

    Time frame: Baseline, 2 years

Secondary outcomes

  1. Change in peak aortic jet velocity

    peak aortic jet velocity (Echocardiography)

    Time frame: Baseline, 2 years

  2. Change in aortic valve area

    Aortic valve area (Echocardiography)

    Time frame: Baseline, 2 years

  3. Change in left ventricular (LV) dimension

    LV dimension (Echocardiography, MRI)

    Time frame: Baseline, 2 years

  4. Change in left ventricular (LV) mass

    LV mass (Echocardiography, MRI)

    Time frame: Baseline, 2 years

  5. Change in left ventricular (LV) fibrosis

    LV Fibrosis (MRI)

    Time frame: Baseline, 2 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Feb 2027, 84 months after the start.

Of 25 phase 4 interventional studies under Aortic Valve Stenosis, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 70. This study's planned 84 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2021
First posted
Jun 4, 2021
StartActual
Feb 1, 2020
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Dec 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04913870
Lead sponsor
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Responsible party
Marie-Annick Clavel (Full Professor, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval) — Principal investigator
First posted
Jun 4, 2021
Start date
Feb 1, 2020
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Dec 20, 2024

Study contacts

Marie-Annick Clavel, PhD
Contact
Marie-Annick.Clavel@criucpq.ulaval.ca
418-656-8711 ext. 2678
Marie-Annick Clavel, PhD
principal investigator · Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Angiotensin receptor blockers (ARBs)

Start the discussion